Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)
Taysha Gene Therapies (TSHA) posted Current Deferred Revenue of $5.5 million for Q3 2025, little changed sequentially from $5.5 million in Q2 2025, and down 53.37% YoY from $11.8 million in Q3 2024.
Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025) Analysis & Trends
Taysha Gene Therapies has reported Current Deferred Revenue for 4 years, with the latest figure at $5.5 million in Q3 2025.
- Quarterly Current Deferred Revenue fell 53.37% year-over-year to $5.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.5 million (down 53.37% YoY) and the FY2024 annual result came in at $9.8 million, down 46.02% from the prior year.
- Current Deferred Revenue held at $5.5 million in Q3 2025 per TSHA's latest filing, from $5.5 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $33.6 million in Q4 2022 and troughed at $5.5 million in Q2 2025.
- A 4-year average of $15.7 million and a median of $14.1 million in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue sank 32.9% in 2024, then plunged 59.51% in 2025.
- Over 4 years, Current Deferred Revenue stood at $33.6 million in 2022, then slumped by 46.04% to $18.1 million in 2023, then slumped by 46.02% to $9.8 million in 2024, then tumbled by 43.72% to $5.5 million in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $5.5 million, $5.5 million, and $7.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 7.50 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Sep 30, 2024 | 11.80 Mn |
| Jun 30, 2024 | 13.58 Mn |
| Mar 31, 2024 | 14.70 Mn |
| Dec 31, 2023 | 18.11 Mn |
| Sep 30, 2023 | 18.80 Mn |
| Jun 30, 2023 | 20.24 Mn |
| Mar 31, 2023 | 28.90 Mn |
| Dec 31, 2022 | 33.56 Mn |